Journal Home > Volume 16 , Issue 11
Nano Research 2023, 16(11): 12864-12879 https://doi.org/10.1007/s12274-023-6273-y
Research Article | Issue | Published: 06 November 2023

Formulated nano-liposomes for reversal of cisplatin resistance in NSCLC with nucleus-targeting peptide

Show Author's Information Minxian Li1,2,3,  Mei Jiang4,  Mengting Chen1,2,  Lilusi Ma1,2,  Xiaocui Fang1,2( ),  Yanlian Yang1,2( ),  Chen Wang1,2( )
Key Laboratory for Biological Effects of Nanomaterials and Nanosafety (Chinese Academy of Sciences), Key Laboratory of Standardization and Measurement for Nanotechnology (Chinese Academy of Sciences), and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China
University of Chinese Academy of Sciences, Beijing 100049, China
Sino-Danish Center for Education and Research, Sino-Danish College, Beijing 101499, China
Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China
Keywords:
cancer therapy, cisplatin resistance, formulated liposome, tumor homing, nucleus-peptide
Topics:
Drug delivery
Cite this article:
Li M, Jiang M, Chen M, et al. Formulated nano-liposomes for reversal of cisplatin resistance in NSCLC with nucleus-targeting peptide. Nano Research, 2023, 16(11): 12864-12879. https://doi.org/10.1007/s12274-023-6273-y
Download citation
EndNote(RIS)
BibTeX

601

Views

128

Downloads

Citations

1

Crossref

0

WoS

0

Scopus

0

CSCD

Abstract Full text Electronic supplementary material About this article

Cell membrane-engineered nano-delivery systems have evolved as a promising strategy to enhance drug bioavailability, offering an alternative for reversing drug resistance in cancer therapy. Herein, a formulated nano-liposome that fabricated by hybridizing cisplatin-resistant A549 cell line (A549/cis) cancer cell membrane and phospholipids for co-delivery of cisplatin and nuclear protein zeste homolog 2 (EZH2)-targeting peptide EIP103, referred to as cLCE, was developed. In vitro results indicated that the formulated nano-liposome can efficiently inhibit A549/cis cancer cell invasion and metastasis through the down-regulation of N-cadherin and vimentin proteins. Mechanistic studies demonstrated that the reduction of nerve growth factor receptor (NGFR) levels and the increase of peroxisome proliferator-activated receptor γ (PPARγ) levels achieved by EIP103 may contribute to the reversal of cisplatin resistance. In vivo results demonstrated that the encapsulation of both cisplatin and EIP103 within cLCE leads to increased intratumoral accumulation and prolonged survival in A549/cis cancer-bearing mice as compared to the individual drugs alone. This can be attributed to the enhanced tumor homing capability of cLCE achieved through the presence of inherited membrane proteins derived from A549/cis cells. Taken together, this study may provide a highly promising therapeutic strategy to improve clinical treatments for cisplatin-resistance non-small-cell lung cancer (NSCLC) as well as other malignant cancers.


menu
Abstract
Full text
Outline
Electronic supplementary material
About this article

Formulated nano-liposomes for reversal of cisplatin resistance in NSCLC with nucleus-targeting peptide

Show Author's information Minxian Li1,2,3, Mei Jiang4, Mengting Chen1,2, Lilusi Ma1,2, Xiaocui Fang1,2( ), Yanlian Yang1,2( ), Chen Wang1,2( )
Key Laboratory for Biological Effects of Nanomaterials and Nanosafety (Chinese Academy of Sciences), Key Laboratory of Standardization and Measurement for Nanotechnology (Chinese Academy of Sciences), and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China
University of Chinese Academy of Sciences, Beijing 100049, China
Sino-Danish Center for Education and Research, Sino-Danish College, Beijing 101499, China
Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China

Abstract

Cell membrane-engineered nano-delivery systems have evolved as a promising strategy to enhance drug bioavailability, offering an alternative for reversing drug resistance in cancer therapy. Herein, a formulated nano-liposome that fabricated by hybridizing cisplatin-resistant A549 cell line (A549/cis) cancer cell membrane and phospholipids for co-delivery of cisplatin and nuclear protein zeste homolog 2 (EZH2)-targeting peptide EIP103, referred to as cLCE, was developed. In vitro results indicated that the formulated nano-liposome can efficiently inhibit A549/cis cancer cell invasion and metastasis through the down-regulation of N-cadherin and vimentin proteins. Mechanistic studies demonstrated that the reduction of nerve growth factor receptor (NGFR) levels and the increase of peroxisome proliferator-activated receptor γ (PPARγ) levels achieved by EIP103 may contribute to the reversal of cisplatin resistance. In vivo results demonstrated that the encapsulation of both cisplatin and EIP103 within cLCE leads to increased intratumoral accumulation and prolonged survival in A549/cis cancer-bearing mice as compared to the individual drugs alone. This can be attributed to the enhanced tumor homing capability of cLCE achieved through the presence of inherited membrane proteins derived from A549/cis cells. Taken together, this study may provide a highly promising therapeutic strategy to improve clinical treatments for cisplatin-resistance non-small-cell lung cancer (NSCLC) as well as other malignant cancers.

Keywords: cancer therapy, cisplatin resistance, formulated liposome, tumor homing, nucleus-peptide

References(67)

[1]

Siegel, R. L.; Miller, K. D.; Wagle, N. S.; Jemal, A. Cancer statistics, 2023. CA A Cancer J Clin. 2023, 73, 17–48
DOI Google Scholar
[2]

Testa, U.; Castelli, G.; Pelosi, E. Lung cancers: Molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers 2018, 10, 248.
DOI Google Scholar
[3]

Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R. L.; Torre, L. A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424.
DOI Google Scholar
[4]

Chen, P. X.; Liu, Y. H.; Wen, Y. K.; Zhou, C. C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022, 42, 937–970
DOI Google Scholar
[5]
Bethesda, MD: National Cancer Institute. PDQ® Adult Treatment Editorial Board. PDQ Non-small cell lung cancer treatment – Health Professional version Feb. 17, 2023 updated [Online]. Aug. 30, 2023. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq.
[6]

Langer, C. J.; Mok, T.; Postmus, P. E. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat. Rev. 2013, 39, 252–260.
DOI Google Scholar
[7]

Rotoli, D.; Santana-Viera, L.; Ibba, M. L.; Esposito, C. L.; Catuogno, S. Advances in oligonucleotide aptamers for NSCLC targeting. Int. J. Mol. Sci. 2020, 21, 6075.
DOI Google Scholar
[8]

Gridelli, C.; Casaluce, F. Frontline immunotherapy for NSCLC: Alone or not alone. Nat. Rev. Clin. Oncol. 2018, 15, 593–594.
DOI Google Scholar
[9]

Garon, E. B.; Hellmann, M. D.; Rizvi, N. A.; Carcereny, E.; Leighl, N. B.; Ahn, M. J.; Eder, J. P.; Balmanoukian, A. S.; Aggarwal, C.; Horn, L. et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 Study. J. Clin. Oncol. 2019, 37, 2518–2527.
DOI Google Scholar
[10]

Stower, H. Effective treatment of NSCLC. Nat. Med. 2020, 26, 1512–1512.
DOI Google Scholar
[11]

Turner, N. C.; Reis-Filho, J. S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012, 13, e178–e185.
DOI Google Scholar
[12]

Gettinger, S. N.; Horn, L.; Gandhi, L.; Spigel, D. R.; Antonia, S. J.; Rizvi, N. A.; Powderly, J. D.; Heist, R. S.; Carvajal, R. D.; Jackman, D. M. et al. Overall survival and long-term safety of Nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 2015, 33, 2004–2012.
DOI Google Scholar
[13]

Ardizzoni, A.; Boni, L.; Tiseo, M.; Fossella, F. V.; Schiller, J. H.; Paesmans, M.; Radosavljevic, D.; Paccagnella, A.; Zatloukal, P.; Mazzanti, P. et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J. Natl. Cancer Inst. 2007, 99, 847–857.
DOI Google Scholar
[14]

Vasconcellos, V. F.; Marta, G. N.; Da Silva, E. M.; Gois, A. F.; De Castria, T. B.; Riera, R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst. Rev. 2020, 1, CD009256.
DOI Google Scholar
[15]

Chen, S. H.; Chang, J. Y. New insights into mechanisms of cisplatin resistance: From tumor cell to microenvironment. Int. J. Mol. Sci. 2019, 20, 4136.
DOI Google Scholar
[16]

Amable, L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016, 106, 27–36.
DOI Google Scholar
[17]

Galluzzi, L.; Vitale, I.; Michels, J.; Brenner, C.; Szabadkai, G.; Harel-Bellan, A.; Castedo, M.; Kroemer, G. Systems biology of cisplatin resistance: Past, present and future. Cell Death Dis. 2014, 5, e1257.
DOI Google Scholar
[18]

Kim, K. H.; Roberts, C. W. M. Targeting EZH2 in cancer. Nat. Med. 2016, 22, 128–134.
DOI Google Scholar
[19]

Varambally, S.; Dhanasekaran, S. M.; Zhou, M.; Barrette, T. R.; Kumar-Sinha, C.; Sanda, M. G.; Ghosh, D.; Pienta, K. J.; Sewalt, R. G. A. B.; Otte, A. P. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419, 624–629.
DOI Google Scholar
[20]

Huqun; Ishikawa, R.; Zhang, J. L.; Miyazawa, H.; Goto, Y.; Shimizu, Y.; Hagiwara, K.; Koyama, N. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer 2012, 118, 1599–1606.
DOI Google Scholar
[21]

Tu, Z. G.; Chen, X. C.; Tian, T.; Chen, G.; Huang, M. J. Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer. Aging 2021, 13, 7397–7415.
DOI Google Scholar
[22]

Wang, X. H.; Zhao, H. Q.; Lv, L.; Bao, L.; Wang, X.; Han, S. G. Prognostic significance of EZH2 expression in non-small cell lung cancer: A meta-analysis. Sci. Rep. 2016, 6, 19239.
DOI Google Scholar
[23]

Zang, X. Y.; Gu, J. M.; Zhang, J. Y.; Shi, H.; Hou, S. N.; Xu, X. Y.; Chen, Y. K.; Zhang, Y.; Mao, F.; Qian, H. et al. Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression. Cell Death Dis. 2020, 11, 215.
DOI Google Scholar
[24]

Xu, C. H.; Hao, K. K.; Hu, H. D.; Sheng, Z. H.; Yan, J.; Wang, Q. B.; Yu, L. K. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy. Lung Cancer 2014, 86, 268–273.
DOI Google Scholar
[25]

Liu, X. Y.; Lu, X. Y.; Zhen, F. X.; Jin, S. D.; Yu, T. F.; Zhu, Q.; Wang, W.; Xu, K.; Yao, J. Q.; Guo, R. H. LINC00665 induces acquired resistance to Gefitinib through recruiting EZH2 and activating PI3K/AKT pathway in NSCLC. Mol. Ther. Nucleic Acids 2019, 16, 155–161.
DOI Google Scholar
[26]

Jiang, M.; Fang, X. C.; Ma, L. L. S.; Liu, M. P.; Chen, M. T.; Liu, J. Y.; Yang, Y. L.; Wang, C. A nucleus-targeting peptide antagonist towards EZH2 displays therapeutic efficacy for lung cancer. Int. J. Pharm. 2022, 622, 121894.
DOI Google Scholar
[27]

Zhang, M.; Liu, E. G.; Cui, Y. N.; Huang, Y. Z. Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biol. Med. 2017, 14, 212.
DOI Google Scholar
[28]

Hu, C. M. J.; Zhang, L. F. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 2012, 83, 1104–1111.
DOI Google Scholar
[29]

Markman, J. L.; Rekechenetskiy, A.; Holler, E.; Ljubimova, J. Y. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv. Drug Deliv. Rev. 2013, 65, 1866–1879.
DOI Google Scholar
[30]

Holder, J. E.; Ferguson, C.; Oliveira, E.; Lodeiro, C.; Trim, C. M.; Byrne, L. J.; Bertolo, E.; Wilson, C. M. The use of nanoparticles for targeted drug delivery in non-small cell lung cancer. Front. Oncol. 2023, 13, 1154318.
DOI Google Scholar
[31]

Chen, J.; Wang, X.; Yuan, Y.; Chen, H. T.; Zhang, L. P.; Xiao, H. H.; Chen, J. Q.; Zhao, Y. X.; Chang, J.; Guo, W. S. et al. Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair-inhibiting (HYDRI) nanomedicine. Sci. Adv. 2021, 7, eabc5267.
DOI Google Scholar
[32]

Chao, M. P.; Weissman, I. L.; Majeti, R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 2012, 24, 225–232.
DOI Google Scholar
[33]

Zeng, Y. P.; Li, S. F.; Zhang, S. F.; Wang, L.; Yuan, H.; Hu, F. Q. Cell membrane coated-nanoparticles for cancer immunotherapy. Acta Pharm. Sin. B. 2022, 12, 3233–3254.
DOI Google Scholar
[34]

Long, Y.; Wang, Z.; Fan, J. L.; Yuan, L. Q.; Tong, C. Y.; Zhao, Y. Z.; Liu, B. A hybrid membrane coating nanodrug system against gastric cancer via the VEGFR2/STAT3 signaling pathway. J. Mater. Chem. B 2021, 9, 3838–3855.
DOI Google Scholar
[35]

Liu, Z. W.; Wang, F. M.; Liu, X. P.; Sang, Y. J.; Zhang, L.; Ren, J. S.; Qu, X. G. Cell membrane-camouflaged liposomes for tumor cell-selective glycans engineering and imaging in vivo. Proc. Natl. Acad. Sci. USA 2021, 118, e2022769118.
DOI Google Scholar
[36]

Li, X. Y.; Yu, Y. Z.; Chen, Q.; Lin, J. B.; Zhu, X. Q.; Liu, X. T.; He, L. Z.; Chen, T. F.; He, W. L. Engineering cancer cell membrane-camouflaged metal complex for efficient targeting therapy of breast cancer. J. Nanobiotechnol. 2022, 20, 401.
DOI Google Scholar
[37]

Cao, H. Q.; Dan, Z. L.; He, X. Y.; Zhang, Z. W.; Yu, H. J.; Yin, Q.; Li, Y. P. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano 2016, 10, 7738–7748.
DOI Google Scholar
[38]

Uemura, Y.; Naoi, T.; Kanai, Y.; Kobayashi, K. The efficiency of lipid nanoparticles with an original cationic lipid as a siRNA delivery system for macrophages and dendritic cells. Pharm. Dev. Technol. 2019, 24, 263–268.
DOI Google Scholar
[39]

Zhou, W.; Wang, J.; Man, W. Y.; Zhang, Q. W.; Xu, W. G. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells. Asian Pac. J. Cancer Prev. 2015, 16, 2425–2430
DOI Google Scholar
[40]

Yang, D. L.; Feng, W. Y.; Zhuang, Y.; Liu, J. X.; Feng, Z. Q.; Xu, T. W.; Wang, W.; Zhu, Y. F.; Wang, Z. X. Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells. Mol. Ther. Nucleic Acids 2021, 23, 1053–1065.
DOI Google Scholar
[41]

Farhood, H.; Serbina, N.; Huang, L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta Biomembr. 1995, 1235, 289–295.
DOI Google Scholar
[42]

Jääskeläinen, I.; Sternberg, B.; Mönkkönen, J.; Urtti, A. Physicochemical and morphological properties of complexes made of cationic liposomes and oligonucleotides. Int. J. Pharm. 1998, 167, 191–203.
DOI Google Scholar
[43]

Liskayová, G.; Hubčík, L.; Búcsi, A.; Fazekaš, T.; Martínez, J. C.; Devínsky, F.; Pisárčik, M.; Hanulová, M.; Ritz, S.; Uhríková, D. pH-sensitive N,N-dimethylalkane-1-amine N-oxides in DNA delivery: From structure to transfection efficiency. Langmuir 2019, 35, 13382–13395
DOI Google Scholar
[44]

Boulikas, T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol. Rep. 2004, 12, 3–12.
DOI Google Scholar
[45]

Ashrafizadeh, M.; Zarrabi, A.; Hushmandi, K.; Kalantari, M.; Mohammadinejad, R.; Javaheri, T.; Sethi, G. Association of the epithelial-mesenchymal transition (EMT) with cisplatin resistance. Int. J. Mol. Sci. 2020, 21, 4002.
DOI Google Scholar
[46]

Cao, Z. Q.; Wang, Z.; Leng, P. Aberrant N-cadherin expression in cancer. Biomed. Pharm. 2019, 118, 109320.
DOI Google Scholar
[47]

Hui, L. P.; Zhang, S. Y.; Dong, X. J.; Tian, D. L.; Cui, Z. S.; Qiu, X. S. Prognostic significance of twist and N-cadherin expression in NSCLC. PLoS One 2013, 8, e62171.
DOI Google Scholar
[48]

Satelli, A.; Li, S. L. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol. Life Sci. 2011, 68, 3033–3046.
DOI Google Scholar
[49]

Kourtidis, A.; Lu, R. F.; Pence, L. J.; Anastasiadis, P. Z. A central role for cadherin signaling in cancer. Exp. Cell Res. 2017, 358, 78–85.
DOI Google Scholar
[50]

Boldin, M. P.; Goncharov, T. M.; Goltseve, Y. V.; Wallach, D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996, 85, 803–815.
DOI Google Scholar
[51]

Muzio, M.; Chinnaiyan, A. M.; Kischkel, F. C.; O'Rourke, K.; Shevchenko, A.; Ni, J.; Scaffidi, C.; Bretz, J. D.; Zhang, M.; Gentz, R. et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996, 85, 817–827
DOI Google Scholar
[52]

Barski, A.; Cuddapah, S.; Cui, K. R.; Roh, T. Y.; Schones, D. E.; Wang, Z. B.; Wei, G.; Chepelev, I.; Zhao, K. J. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129, 823–837.
DOI Google Scholar
[53]

Dawson, M. A.; Kouzarides, T. Cancer epigenetics: From mechanism to therapy. Cell 2012, 150, 12–27.
DOI Google Scholar
[54]

Zaib, S.; Rana, N.; Khan, I. Histone modifications and their role in epigenetics of cancer. Curr. Med. Chem. 2022, 29, 2399–2411.
DOI Google Scholar
[55]

Greer, E. L.; Shi, Y. Histone methylation: A dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 2012, 13, 343–357.
DOI Google Scholar
[56]

Margueron, R.; Reinberg, D. The polycomb complex PRC2 and its mark in life. Nature 2011, 469, 343–349.
DOI Google Scholar
[57]

Moufarrij, S.; Dandapani, M.; Arthofer, E.; Gomez, S.; Srivastava, A.; Lopez-Acevedo, M.; Villagra, A.; Chiappinelli, K. B. Epigenetic therapy for ovarian cancer: Promise and progress. Clin. Epigenet. 2019, 11, 7.
DOI Google Scholar
[58]

Gao, W.; Zhang, J.; Zhang, M. J.; Hu, L. Y.; Wong, T. S.; Chan, J. Y. W. The functional role of NGFR in regulating chemosensitivity in nasopharyngeal carcinoma. Ann. Oncol. 2018, 29, vii72.
DOI Google Scholar
[59]

Huang, J.; Yu, Q. H.; Zhou, Y. J.; Chu, Y.; Jiang, F.; Zhu, X. B.; Zhang, J. J.; Wang, Q. A positive feedback loop formed by NGFR and FOXP3 contributes to the resistance of non-small cell lung cancer to icotinib. Transl. Cancer Res. 2020, 9, 1044–1052.
DOI Google Scholar
[60]

Zhang, J.; Zeng, Y. Y.; Xing, Y. P.; Li, X. R.; Zhou, L. Q.; Hu, L.; Chin, Y. E.; Wu, M. Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth. Cancer Lett. 2021, 516, 84–98.
DOI Google Scholar
[61]

Lu, Z. H.; Fang, Z.; Guo, Y.; Liu, X. F.; Chen, S. J. Cisplatin resistance of NSCLC cells involves upregulation of visfatin through activation of its transcription and stabilization of mRNA. Chem. Biol. Interact. 2022, 351, 109705.
DOI Google Scholar
[62]

Mukherjee, T. K.; Paul, K.; Mukhopadhyay, S. Cell signaling molecules as drug targets in lung cancer: An overview. Curr. Opin. Pulm. Med. 2011, 17, 286–291.
DOI Google Scholar
[63]

Hu, F. F.; Chen, H.; Duan, Y.; Lan, B.; Liu, C. J.; Hu, H.; Dong, X.; Zhang, Q.; Cheng, Y. M.; Liu, M. et al. CBX2 and EZH2 cooperatively promote the growth and metastasis of lung adenocarcinoma. Mol. Ther. Nucleic Acids 2022, 27, 670–684.
DOI Google Scholar
[64]

Kim, T. W.; Hong, D. W.; Kang, C. M.; Hong, S. H. A novel PPARɣ ligand, PPZ023, overcomes radioresistance via ER stress and cell death in human non-small-cell lung cancer cells. Exp. Mol. Med. 2020, 52, 1730–1743.
DOI Google Scholar
[65]

Hu, S.; Yu, L. L.; Li, Z. M.; Shen, Y.; Wang, J.; Cai, J.; Xiao, L.; Wang, Z. H. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol. Ther. 2010, 10, 788–795.
DOI Google Scholar
[66]

Rizzo, S.; Hersey, J. M.; Mellor, P.; Dai, W.; Santos-Silva, A.; Liber, D.; Luk, L.; Titley, I.; Carden, C. P.; Box, G. et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther. 2011, 10, 325–335.
DOI Google Scholar
[67]

Dou, D. W.; Ge, X.; Wang, X. X.; Xu, X. D.; Zhang, Z.; Seng, J.; Cao, Z.; Gu, Y. T.; Han, M. L. EZH2 contributes to cisplatin resistance in breast cancer by epigenetically suppressing miR-381 expression. Onco Targets Ther. 2019, 12, 9627–9637
DOI Google Scholar
File
12274_2023_6273_MOESM1_ESM.pdf (1.4 MB)
Publication history
Copyright
Acknowledgements

Publication history

Received: 03 September 2023
Revised: 05 October 2023
Accepted: 16 October 2023
Published: 06 November 2023
Issue date: November 2023

Copyright

© Tsinghua University Press 2023

Acknowledgements

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Nos. 32101130, 21721002, and 31971295). Financial support from Strategic Priority Research Program of Chinese Academy of Sciences (No. XDB36000000) is also gratefully acknowledged.

Return